Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Orange Book Patents
Across 2 drugs with upcoming expirations
Activity
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Regulatory
Lopressor — LOPRESSOR
Application NDA019786 (NDA)
Zovirax — ZOVIRAX
Application NDA019909 (NDA)
Retrovir — RETROVIR
Application NDA019910 (NDA)
Zovirax — ZOVIRAX
Application NDA018603 (NDA)
Retrovir — RETROVIR
Application NDA019951 (NDA)
Zovirax — ZOVIRAX
Application NDA020089 (NDA)
Retrovir — RETROVIR
Application NDA020518 (NDA)
Calcimar — MIACALCIN
Application NDA020313 (NDA)
Lotrimin Ultra — MENTAX
Application NDA020524 (NDA)
Lotrimin Ultra — LOTRIMIN ULTRA
Application NDA021307 (NDA)
Lopressor — TOPROL-XL
Application NDA019962 (NDA)
Zovirax — ZOVIRAX
Application NDA021478 (NDA)
Lotrimin Ultra — MENTAX-TC
Application NDA021408 (NDA)
Retrovir — ZIDOVUDINE
Application NDA022294 (NDA)
Retrovir — ZIDOVUDINE
Application NDA200732 (NDA)
Zovirax — SITAVIG
Application NDA203791 (NDA)
Lopressor — KAPSPARGO SPRINKLE
Application NDA210428 (NDA)
Zovirax — AVACLYR
Application NDA202408 (NDA)
Lopressor — LOPRESSOR
Application NDA218698 (NDA)
Lopressor — LOPRESSOR
Application NDA219373 (NDA)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)